Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Biocept, Inc. (NASDAQ: BIOC).

Full DD Report for BIOC

You must become a subscriber to view this report.


Recent News from (NASDAQ: BIOC)

Guardant Health on deck for IPO
Redwood City, CA-based Guardant Health ( GH ) has filed a prospectus for a $100M IPO. More news on: Guardant Health, TrovaGene, Inc., Roche Holding Ltd ADR, Healthcare stocks news, IPOs, Read more ...
Source: SeekingAlpha
Date: September, 06 2018 10:55
Biocept's Target Selector Platform Featured in Two Poster Presentations at the IASLC 19th World Conference on Lung Cancer
SAN DIEGO , Sept. 6, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that two poster pr...
Source: PR Newswire
Date: September, 06 2018 08:05
Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer
PITTSBURGH and SAN DIEGO , Aug. 23, 2018 /PRNewswire/ -- Highmark Health announced today that through its VITAL Innovation Program, it is testing Biocept, Inc.'s Target Selector™ liquid biopsy platform designed to help oncologists improve the diagnosis and treatment of patie...
Source: PR Newswire
Date: August, 23 2018 10:30
Biocept's (BIOC) CEO Michael Nall on Q2 2018 Results - Earnings Call Transcript
Biocept, Inc. (BIOC) Q2 2018 Earnings Conference Call August 14, 2018 4:30 PM ET Executives Jody Cain – LHA Investor Relations Michael Nall – President and Chief Executive Officer Tim Kennedy – Senior Vice President of Operations and Chief Financial Officer ...
Source: SeekingAlpha
Date: August, 14 2018 20:45
Biocept Q2 revenue miss pressures shares, down 4% after hours
Biocept (NASDAQ: BIOC ) Q2 results ($M): Revenues: 0.8 (-38%); net loss: (5.7) (+8%); loss/share: (6.32) ( -134%). Revenue drop influenced by transition from cash-based revenue recognition to accrual. Revenues were down 25% yoy on an accrual basis. More news on: Biocept, Inc., Healthcare...
Source: SeekingAlpha
Date: August, 14 2018 16:40
Biocept beats by $0.60, misses on revenue
Biocept (NASDAQ: BIOC ): Q2 EPS of -$2.70 beats by $0.60 . More news on: Biocept, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 14 2018 16:21
Biocept Reports Second Quarter 2018 Financial Results
SAN DIEGO , Aug. 14, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and...
Source: PR Newswire
Date: August, 14 2018 16:05
Biocept to Release Second Quarter 2018 Financial Results and Host Investor Conference Call on August 14, 2018
SAN DIEGO , Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will relea...
Source: PR Newswire
Date: August, 09 2018 16:05
Biocept Announces $11.6 Million in Expected Gross Proceeds from Recently Expired Rights Offering
SAN DIEGO , Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announced today that the Company's previously ...
Source: PR Newswire
Date: August, 09 2018 08:05
Biocept Announces Agreement with Managed Care Plan to Study the Benefits of Implementing Liquid Biopsy to Improve Patient Outcomes and Lower Healthcare Costs
SAN DIEGO , Aug. 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into an agreemen...
Source: PR Newswire
Date: August, 06 2018 08:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-170.790.66910.810.658290,296
2018-12-140.760.78180.840.7201318,250
2018-12-130.84050.76610.919990.755216,810
2018-12-120.840.84130.950.84153,334
2018-12-110.950.83980.970.801313,263

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1729,93858,50451.1726Short
2018-12-1451,73088,06358.7420Short
2018-12-1324,79153,35846.4616Short
2018-12-1216,71536,74145.4941Short
2018-12-1121,92367,31032.5702Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BIOC.


About Biocept, Inc. (NASDAQ: BIOC)

Logo for Biocept, Inc. (NASDAQ: BIOC)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $2,644,862 - 03/20/2018
    • Issue and Outstanding: 8,396,387 - 09/29/2016

     


    Recent Filings from (NASDAQ: BIOC)

    Preliminary proxy statement providing notification matters to be brought to a vote
    Filing Type: PRE 14AFiling Source: edgar
    Filing Date: May, 17 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 15 2018
    Simplified registration form
    Filing Type: S-3Filing Source: edgar
    Filing Date: May, 15 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 15 2018
    Amendment to a previously filed 10-K
    Filing Type: 10-K/AFiling Source: edgar
    Filing Date: April, 30 2018
    Amendment to a previously filed 10-K
    Filing Type: 10-K/AFiling Source: edgar
    Filing Date: April, 30 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 06 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 06 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 28 2018
    Annual report with a comprehensive overview of the company
    Filing Type: 10-KFiling Source: edgar
    Filing Date: March, 28 2018

     

     


    Daily Technical Chart for (NASDAQ: BIOC)

    Daily Technical Chart for (NASDAQ: BIOC)


    Stay tuned for daily updates and more on (NASDAQ: BIOC)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: BIOC)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BIOC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BIOC and does not buy, sell, or trade any shares of BIOC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/